Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

 Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

Shots:

  • The first patient has been dosed in the P-II AAVIATE trial to assess the suprachoroidal delivery of RGX-314 (2.5×1011 GC/eye & 5×1011 GC/eye) vs ranibizumab (0.5mg, monthly, IVT) using the SCS Microinjector in ~40 patients in a ratio (3:1) with wet AMD
  • The 1EPs of the study is mean change in vision in patients dosed with RGX-314, as measured by BCVA @40wks., other endpoints include mean change in CRT and number of anti-VEGF IVT received following administration of RGX-314
  • The company expects to report interim data of the first cohort of the trial by the end of 2020. RGX-314 is consists of the NAV AAV8 vector, being developed as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions and has shown a positive effect in patients with wet AMD when delivered subretinally in the ongoing P-I/IIa study

Click here ­to­ read full press release/ article | Ref: Regenxbio | Image: Regenxbio

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post